Pancreatic Cancer Research

ResearcherAnkara Numune Eğitim ve Araştırma HastanesiActive in the last 2 years

Nuriye Özdemir

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-9235-9592; OpenAlex author ID A5006363327, A5113757725. Sources: OpenAlex.

Their work

Papers
9 (first author 2, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
25
Papers, trials and grants by year

2012: 4 papers · 2013: none · 2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: none · 2022: none · 2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper

Papers 9

  1. FOLFIRINOX for Locally Advanced Pancreatic Cancer: The Need for Individualized Strategies. Last author DOI 10.1200/jco-25-01214↗
  2. Retrospective Evaluation of the Efficacy of Gemcitabine-Based Therapies After FOLFIRINOX Failure in Advanced Pancreatic Cancer, Multi-Center Real-Life Data. Last author DOI 10.1097/mpa.0000000000002238↗
  3. Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine+nab-paclitaxel versus gem… Co-author DOI 10.1186/s12885-020-06758-9↗
  4. Comparison of Gemcitabine monotherapy with Gemcitabine and Cisplatin combination in metastatic pancreatic cancer: a retrospective analysis. First author PMID 30722120↗
  5. Evaluation of the effect of comorbidity on survival in pancreatic cancer by using "Charlson Comorbidity Index" and "Cumulative Illness Rating Scale". Co-author DOI 10.1007/s00508-013-0453-9↗
  6. XELOX vs. FOLFOX4 as second line chemotherapy in advanced pancreatic cancer. First author DOI 10.5754/hge12181↗
  7. Is there an association between blood group and survival in pancreatic cancer? Co-author DOI 10.7314/apjcp.2012.13.12.6151↗
  8. Long term survivors with metastatic pancreatic cancer treated with gemcitabine alone or plus cisplatin: a retrospective analysis of an Anatolian Society of Med… Co-author DOI 10.7314/apjcp.2012.13.5.1841↗
  9. Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cisplatin: retrospective analysis of a multic… Co-author PMID 22517701↗

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Osman Sütçüoğlu · 2 shared papers, 2023–2026 · strength 0.52
  2. Orhun Akdoğan · 1 shared paper, 2026 · strength 0.39
  3. Metin Özkan · 4 shared papers, 2012–2020 · strength 0.16
  4. Nurullah Zengin · 3 shared papers, 2012–2018 · strength 0.14
  5. Taha Koray Şahin · 1 shared paper, 2023 · strength 0.14
  6. Ömer Dızdar · 1 shared paper, 2023 · strength 0.14
  7. Abdurrahman Işıkdoğan · 3 shared papers, 2012–2020 · strength 0.14
  8. Fahriye Tuğba Köş · 4 shared papers, 2012–2014 · strength 0.12
  9. Nuri Faruk Aykan · 1 shared paper, 2020 · strength 0.09
  10. Saadettin Kılıçkap · 1 shared paper, 2020 · strength 0.09
  11. Türkkan Evrensel · 1 shared paper, 2020 · strength 0.09
  12. Şuayib Yalçın · 1 shared paper, 2020 · strength 0.09
  13. Velı Berk · 3 shared papers, 2012 · strength 0.08
  14. Ali̇ İnal · 3 shared papers, 2012 · strength 0.08
  15. Doğan Uncu · 2 shared papers, 2012–2014 · strength 0.08
  16. Nebi Serkan Demirci · 1 shared paper, 2018 · strength 0.07
  17. Hüseyin Engin · 1 shared paper, 2018 · strength 0.07
  18. İsa Dede · 1 shared paper, 2018 · strength 0.07
  19. Elif Berna Köksoy · 1 shared paper, 2018 · strength 0.07
  20. Yüksel Ürün · 1 shared paper, 2018 · strength 0.07
  21. Yakup Ergün · 1 shared paper, 2018 · strength 0.07
  22. Mahmut Gümüş · 2 shared papers, 2012 · strength 0.05
  23. Olçun Ümit Ünal · 1 shared paper, 2012 · strength 0.03
  24. Özlem Sönmez · 1 shared paper, 2012 · strength 0.03
  25. Gamze Göksel Ozturk · 1 shared paper, 2012 · strength 0.02

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.